An Overview of Biomarkers for the Diagnosis of Hepatocellular Carcinoma

Overview

Journal Hepat Mon

Publisher Brieflands

Specialty Gastroenterology

Date 2012 Nov 20

PMID 23162601

Citations 13

Authors

Mona Abu El Makarem

Affiliations

Soon will be listed here.

Abstract

Context: Primary liver cancer is one of the most common and deadly malignant neoplasms worldwide. The incidence and mortality rates for hepatocellular carcinoma (HCC) are virtually identical, reflecting the poor overall survival of patients with this kind of tumor. Effective therapies mostly achieved if the HCC diagnosis is made at early stages of the tumor. Surveillance tests include serologic and radiologic examinations.

Evidence Acquisition: In this review, an overview of biomarkers for the diagnosis of HCC and future challenges in this popular field has been presented.

Results: Serum tumor markers, such as alpha-fetoprotein (AFP) and des-gammacarboxy prothrombin (DCP) are commonly used for the surveillance, but their roles have been intensely debated despite the existence of sensitive radiologic tests. Most HCC-related cancer biomarkers are involved in chronic inflammation and cancer. These biomarkers, according to their biologic characteristics are primarily divided into three groups including onco-foetal protein, stress protein, and post-translational modification.

Conclusions: Because of the limitations of traditional HCC biomarkers, exploration for novel biomarkers for the diagnosis of HCC is an evolving process.

Citing Articles

Influence of Alanine Transaminase Levels on Alpha-Fetoprotein for Predicting Hepatocellular Carcinoma in Patients with Hepatitis B Infection.

Chen J, Wu M, Gong J, Liu Z, He G, Zhu H Biomed Res Int. 2021; 2020:2043715.

PMID: 33490235 PMC: 7787738. DOI: 10.1155/2020/2043715.

Evaluation of plasma D-dimer for the diagnosis in Chinese patients with hepatocellular carcinoma: A meta-analysis.

Fang P, Du L, Cai D Medicine (Baltimore). 2020; 99(12):e19461.

PMID: 32195943 PMC: 7220415. DOI: 10.1097/MD.0000000000019461.

Diagnostic Value of Glypican-3 for Hepatocellular Carcinomas.

El-Saadany S, El-Demerdash T, Helmy A, Mayah W, Hussein B, Hassanien M Asian Pac J Cancer Prev. 2018; 19(3):811-817.

PMID: 29582639 PMC: 5980860. DOI: 10.22034/APJCP.2018.19.3.811.

Variety and Dynamics of Proteoforms in the Human Proteome: Aspects of Markers for Hepatocellular Carcinoma.

Naryzhny S, Zgoda V, Kopylov A, Petrenko E, Kleist O, Archakov A Proteomes. 2017; 5(4).

PMID: 29168748 PMC: 5748568. DOI: 10.3390/proteomes5040033.

Hepatocellular carcinoma: Review of disease and tumor biomarkers.

Kim J, Shariff M, Crossey M, Gomez-Romero M, Holmes E, Cox I World J Hepatol. 2016; 8(10):471-84.

PMID: 27057305 PMC: 4820639. DOI: 10.4254/wjh.v8.i10.471.

References

Khattab M, Eslam M, Sharwae M, Hamdy L . Seroprevalence of hepatitis C and B among blood donors in Egypt: Minya Governorate, 2000-2008. Am J Infect Control. 2010; 38(8):640-1. DOI: 10.1016/j.ajic.2009.12.016. View

Suzuki M, Shiraha H, Fujikawa T, Takaoka N, Ueda N, Nakanishi Y . Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma. J Biol Chem. 2004; 280(8):6409-15. DOI: 10.1074/jbc.M406714200. View

Li D, MALLORY T, Satomura S . AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta. 2001; 313(1-2):15-9. DOI: 10.1016/s0009-8981(01)00644-1. View

Iftikhar R, Kladney R, Havlioglu N, Schmitt-Graff A, Gusmirovic I, Solomon H . Disease- and cell-specific expression of GP73 in human liver disease. Am J Gastroenterol. 2004; 99(6):1087-95. DOI: 10.1111/j.1572-0241.2004.30572.x. View

Debruyne E, Delanghe J . Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta. 2008; 395(1-2):19-26. DOI: 10.1016/j.cca.2008.05.010. View

Lehman E, Wilson M . Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: a systematic review and meta-analysis. Int J Cancer. 2008; 124(3):690-7. DOI: 10.1002/ijc.23937. View

Sterling R, Jeffers L, Gordon F, Sherman M, Venook A, Reddy K . Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol. 2007; 102(10):2196-205. DOI: 10.1111/j.1572-0241.2007.01405.x. View

Filmus J, Capurro M . The role of glypican-3 in the regulation of body size and cancer. Cell Cycle. 2008; 7(18):2787-90. DOI: 10.4161/cc.7.18.6672. View

Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y . Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2006; 4(1):111-7. DOI: 10.1016/s1542-3565(05)00855-4. View

10.

Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y . Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun. 2003; 306(1):16-25. DOI: 10.1016/s0006-291x(03)00908-2. View

11.

Croce M, Isla-Larrain M, Demichelis S, Gori J, Price M, Segal-Eiras A . Tissue and serum MUC1 mucin detection in breast cancer patients. Breast Cancer Res Treat. 2003; 81(3):195-207. DOI: 10.1023/A:1026110417294. View

12.

Marrero J, Su G, Wei W, Emick D, Conjeevaram H, Fontana R . Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology. 2003; 37(5):1114-21. DOI: 10.1053/jhep.2003.50195. View

13.

Mann C, Neal C, Garcea G, Manson M, Dennison A, Berry D . Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer. 2007; 43(6):979-92. DOI: 10.1016/j.ejca.2007.01.004. View

14.

Gomaa A, Khan S, Toledano M, Waked I, Taylor-Robinson S . Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008; 14(27):4300-8. PMC: 2731180. DOI: 10.3748/wjg.14.4300. View

15.

Capurro M, Wanless I, Sherman M, Deboer G, Shi W, Miyoshi E . Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003; 125(1):89-97. DOI: 10.1016/s0016-5085(03)00689-9. View

16.

Looi K, Nakayasu E, Diaz R, Tan E, Almeida I, Zhang J . Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma. J Proteome Res. 2008; 7(9):4004-12. PMC: 2680441. DOI: 10.1021/pr800273h. View

17.

Pan H, Ou Y, Peng S, Liu S, Lai P, Lee P . Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer. 2003; 98(1):119-27. DOI: 10.1002/cncr.11487. View

18.

Shevde L, Das S, Clark D, Samant R . Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med. 2010; 10(1):71-81. PMC: 6869338. DOI: 10.2174/156652410791065381. View

19.

Sterling R, Jeffers L, Gordon F, Venook A, Reddy K, Satomura S . Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2008; 7(1):104-13. DOI: 10.1016/j.cgh.2008.08.041. View

20.

BERGSTRAND C, CZAR B . Demonstration of a new protein fraction in serum from the human fetus. Scand J Clin Lab Invest. 1956; 8(2):174. DOI: 10.3109/00365515609049266. View